Research programme: trivalent recombinant human influenza subunit vaccine - Cilian

Drug Profile

Research programme: trivalent recombinant human influenza subunit vaccine - Cilian

Alternative Names: CiFlu; Glide influenza virus vaccine

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cilian
  • Developer Cilian; Glide Technologies
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Influenza virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Germany (Parenteral)
  • 21 Sep 2015 Cilian and Glide Technologies agree to develop a solid formulation of CiFlu® for Influenza virus infections
  • 21 Sep 2015 Early research in Influenza virus infections in Germany (PO) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top